Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals REGN

$ 701.48 0.78%

Annual report 2024
added 02-05-2025

report update icon

Country

usaUSA

IPO year

1991

Industry

Biotechnology

Stock Exchange

NASDAQ GLOBALSPB

CEO

Dr. Leonard Schleifer

Employees in the company

8 314

Shares

108 M

Market Cap[1]

$ 75.7 B

EBITDA (LTM)

$ 4.49 B

P/E (LTM)

20.04

P/S (LTM)

6.49

EPS (LTM)

41.83

Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.

Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.

One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.

The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.

Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
CureVac N.V. CureVac N.V.
CVAC
$ 3.33 1.45 % $ 619 M Nasdaq Global Market germanyGermany
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 14.47 0.56 % $ 371 M Nasdaq Global Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.26 -2.23 % $ 221 M Nasdaq Global Market usaUSA
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
$ 0.29 -18.52 % $ 27.3 M Nasdaq Global Select Market britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 2.13 -2.74 % $ 78.5 M Nasdaq Capital Market israelIsrael
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
$ 5.72 5.93 % $ 314 M Nasdaq Capital Market canadaCanada
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.15 -1.51 % $ 35.3 M Nasdaq Global Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Kiromic BioPharma Kiromic BioPharma
KRBP
$ 3.15 6.61 % $ 3.08 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.